Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1533-1536

  Fischer, J ^a   Van Koningsbruggen Rietschel, S ^a   Rietschel, E ^a   Vehreschild, M J G T ^b   Wisplinghoff, H ^a   Kronke M ^a   Hamprecht, A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cyp51A; TR34 L98H; TR46 Y121F T289A

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; PYRROLE; VORICONAZOLE; ANTIFUNGAL AGENT; FUNGAL PROTEIN; PYRROLE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLUS; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENE MUTATION; GERMANY; HUMAN; MALE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; SEQUENCE ANALYSIS; ADOLESCENT; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; CHILD; COMPLICATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MUTATION; NEWBORN; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; AZOLES; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; PREVALENCE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84901765409     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku009     Document Type: Article

References (20)

1. Bakare N, Rickerts V, Bargon J et al. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003; 46: 19-23.
2. Chowdhary A, Kathuria S, Xu J et al. Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR(3)(4)/L98H mutations in the cyp51A gene in India. PLoS One 2012; 7: e52871.
3. Howard SJ, Pasqualotto AC, Denning DW. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect 2010; 16: 683-8.
4. van der Linden JW, Snelders E, Kampinga GA et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011; 17: 1846-54.
5. Verweij PE, Howard SJ, Melchers WJ et al. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat 2009; 12: 141-7.
6. Hamprecht A, Buchheidt D, Vehreschild JJ et al. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill 2012; 17: pii=20262.
7. Rath PM, Buchheidt D, Spiess B et al. First reported case of azole-resistant Aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob Agents Chemother 2012; 56: 6060-1.
8. Snelders E, Camps SM, Karawajczyk A et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 2012; 7: e31801.
9. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-76.
10. Glass NL, Donaldson GC. Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes. Appl Environ Microbiol 1995; 61: 1323-30.
11. Chen J, Li H, Li R et al. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother 2005; 55: 31-7.
12. Rodriguez-Tudela JL, Arendrup MC, Arikan S et al. EUCAST DEFINITIVE DOCUMENT E.DEF 9.1: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST EDEF 91 2008: 1-13.
13. Bargon J, Dauletbaev N, Kohler B et al. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 1999; 93: 835-8.
14. Bader O, Weig M, Reichard U et al. cyp51A-based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother 2013; 57: 3513-7.
15. Morio F, Aubin GG, Danner-Boucher I et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 2012; 67: 1870-3.
16. Mortensen KL, Jensen RH, Johansen HK et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011; 49: 2243-51.
17. van der Linden JW, Camps SM, Kampinga GA et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57: 513-20.
18. Camps SM, Rijs AJ, Klaassen CH et al. Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol 2012; 50: 2674-80.
19. Vermeulen E, Maertens J, Schoemans H et al. Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium, July 2012. Euro Surveill 2012; 17: pii=20326.
20. Chowdhary A, Sharma C, Kathuria S et al. Azole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in India. J Antimicrob Chemother 2014; 69: 555-7.